The board of directors of Sanofi (SNY) have proposed an annual dividend of €3.92 per share, an increase of 4.26% from prior dividend of €3.76 per share.

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit ...

In talking with his son about past Easter egg hunts, columnist Joe MacDonald recalls a lesson on finding strength amid adversity.

The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.

Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

The latest development follows Sanofi's recent FDA approval for its haemophilia treatment, Qfitlia (fitusiran). "FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions" was originally ...